Integra LifeSciences Holdings Corporation
) announced the publication of the clinical study, Collagen
Conduit Versus Microsurgical Neurorraphy, in the December issue
of The Journal of Hand Surgery.
ACTELION LTD (ALIOF): Get Free Report
HESKA CORP (HSKA): Free Stock Analysis Report
INTEGRA LIFESCI (IART): Free Stock Analysis
VANDA PHARMACT (VNDA): Free Stock Analysis
To read this article on Zacks.com click here.
The study, which spanned through two years and covered thirty two
patients, primarily focused on NeuraGen Nerve Guide and other
traditional methods of direct suture repair in patients who
suffered from traumatic nerve injuries. It was a two-year follow
up of a controlled, randomized, blind multi-center study of
peripheral nerve repair.
All the 32 patients completed the two-year post-operative
follow-up period, during which they underwent regular examination
of sensory and motor electrophysiological function,
post-operative pain assessments and overall hand function.
The results released bring to light some interesting facts.
Operation time can be cut down by more than 40% using the
collagen conduit than performing direct suture repair. Moreover,
patients who were treated with NeuraGen Nerve Guide also reported
lower post-operative pain than those treated with direct repair.
NeuraGen Nerve Guide is a semi-permeable bovine collagen tube
designed to be used as an interface for damaged nerves and the
Integra has been dedicating a lot of its resources towards
developing this product, considering the tremendous global
potential of the U.S peripherals nerve repair market. The market
potential has been estimated at $1.32 to $1.93 billion, by the
Magellan Medical Technology Consultants, Inc. ("MMTC").
IART has already received the FDA clearance for the device
in 2001, followed with the CE Mark in Europe in 2003.
Integra is encouraged by the fact that entubulation nerve repair
using the NeuraGen Nerve Guide matches the highly-esteemed
standard of microsurgical suture. Management is optimistic that
the study publication will induce fast adoption of the nerve
conduit and will favorably contribute to revenues.
Currently, Integra LifeSciences Holdings Corporation carries a
Zacks Rank #3 (Hold). Investors interested in the industry may
also consider stocks like
Vanda Pharmaceuticals, Inc
). All these stocks sport a Zacks Rank #1 (Strong Buy).